The Cigna Group
CI
$277.51
+1.13%
The Cigna Group is a diversified healthcare company that provides health insurance and pharmacy benefit management (PBM) services, primarily in the United States. Its PBM and specialty pharmacy operations, expanded through the 2018 Express Scripts merger, serve health plans and employers, including a major contract with the Department of Defense and a recent multiyear deal with Centene. Cigna is a major player in the healthcare services space, competing with UnitedHealth and CVS Health, and is currently undergoing a strategic review of its eviCore business and exiting the individual exchange market, while raising its full-year outlook. The investor narrative centers on the company's ability to execute its strategic pivot, manage margin pressures in its PBM segment, and deliver on its raised guidance.…
CI
The Cigna Group
$277.51
Related headlines
Investment Opinion: Should I buy CI Today?
Based on the analysis, I rate Cigna as a Buy. The stock is trading at a forward PE of 8.44x, which is attractive given the expected EPS growth, and the consensus analyst target of $341.42 implies a 20.8% upside. The company's raised guidance and strong free cash flow of $7.66 billion support the thesis that the market is undervaluing its earnings power.
Sign up to view all
CI 12-Month Price Forecast
The AI assessment leans bullish due to the compelling valuation and positive analyst sentiment. The forward PE of 8.44x suggests the market is pricing in significant earnings growth, which is supported by the company's raised guidance and strong cash flow. However, the medium confidence reflects the risks of margin pressure and strategic execution. If the company delivers on its guidance and successfully executes its strategic review, the stock could re-rate higher. Conversely, any negative surprises on margins or contracts would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $341.42 and implied upside of +23.0% versus the current price.
Average Target
$341.42
0 analysts
Implied Upside
+23.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
The target price range spans from a low of $290.00 to a high of $400.00, representing a wide spread of $110.00, which signals high uncertainty about Cigna's future performance. The high target of $400 assumes successful execution of the strategic review, margin expansion, and robust growth in the PBM segment, while the low target of $290 reflects concerns about competitive pressures, regulatory risks, and potential margin compression. Recent institutional ratings show a mix of upgrades and downgrades, with Barclays and Deutsche Bank lowering their ratings, while UBS and Guggenheim maintain buy ratings, suggesting that analysts are divided on the stock's near-term prospects.
Bulls vs Bears: CI Investment Factors
Cigna presents a mixed picture: it is fundamentally undervalued with a forward PE of 8.44x and a consensus 'Buy' rating, but it has underperformed the market significantly and faces strategic execution risks. The bull case is supported by strong analyst targets and solid cash flow, while the bear case is driven by margin pressures and competitive challenges. Currently, the evidence slightly favors the bull side due to the compelling valuation and upside potential, but the key tension lies in whether the company can successfully execute its strategic pivot and improve margins. If the strategic review leads to divestitures that unlock value, the stock could re-rate higher; otherwise, it may continue to languish.
Bullish
- Attractive Valuation with Low Forward PE: Cigna trades at a forward PE of 8.44x, a 31.6% discount to its trailing PE of 12.34x, implying strong expected earnings growth. The PEG ratio of 0.15x suggests the stock is undervalued relative to its growth prospects, making it an attractive entry point for value investors.
- Strong Analyst Consensus and Upside: With 24 analysts covering the stock, the consensus rating is 'Buy' (mean 1.67) and the average target price is $341.42, representing a 20.8% upside from the current price of $282.56. The high target of $400 implies a 41.6% upside, reflecting confidence in the company's strategic initiatives.
- Revenue Growth and Raised Guidance: Q1 2026 revenue grew 4.57% YoY to $68.49 billion, and the company raised its full-year outlook, signaling confidence in its operational performance. The Evernorth segment, which contributes $58.44 billion in revenue, continues to drive growth, supported by major contracts like the Department of Defense and Centene.
- Solid Profitability and Cash Flow: Cigna generates strong free cash flow of $7.66 billion TTM, supporting its dividend yield of 2.2% and share repurchases. The operating margin of 3.32% and net margin of 2.17% are stable, and the ROE of 14.28% indicates efficient capital utilization.
Bearish
- Underperformance and Negative Relative Strength: Cigna has underperformed the S&P 500 by 23.05% over the past year, with a 1-year price change of -2.68% versus the SPY's +20.37%. The stock's relative strength is negative across all timeframes, indicating persistent selling pressure and investor skepticism.
- Strategic Execution Risks: The company is exiting the individual exchange market and reviewing its eviCore business, which introduces execution risk. These strategic pivots could disrupt operations and create uncertainty, as highlighted in recent news about the raised outlook but flagged risks.
- Margin Pressure in PBM Segment: Gross margin is only 9.45%, reflecting the low-margin nature of the PBM business. Operating margin of 3.32% is thin, and any increase in drug costs or pricing pressure from clients could compress margins further, impacting profitability.
- High Debt Levels: The debt-to-equity ratio of 0.75x indicates a significant debt burden, which could limit financial flexibility. Interest expenses of $357 million in Q1 2026 are substantial, and rising interest rates could increase borrowing costs, affecting net income.
CI Technical Analysis
Cigna's stock has been in a broad range-bound consolidation over the past year, with the current price of $282.56 sitting near the middle of its 52-week range of $239.51 to $315.47, representing about 62% of the range. The 1-year price change is -2.68%, indicating a slight decline, while the stock has underperformed the S&P 500 significantly, with relative strength of -23.05% over the same period. This positioning suggests a lack of clear directional momentum, with the stock neither at highs nor lows, reflecting investor uncertainty.
Beta
0.32
0.32x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
-7.8%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +2.5% |
| 3m | -3.0% | +2.7% |
| 6m | -1.0% | +11.1% |
| 1y | -7.8% | +20.5% |
| ytd | -0.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory shows steady growth, with Q1 2026 revenue of $68.49 billion, up 4.57% year-over-year from $65.50 billion in Q1 2025. The multi-quarter trend indicates consistent expansion, with revenue rising from $60.52 billion in Q2 2024 to $68.49 billion in Q1 2026, though growth has been modest at around 4-5% annually. The Evernorth segment, which includes PBM services, drives the majority of revenue at $58.44 billion, while Cigna Healthcare contributes $11.48 billion, highlighting the company's reliance on its PBM business for growth.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given that Cigna has positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 12.34x, while the forward PE is 8.44x, indicating that the market expects significant earnings growth, with the forward multiple implying a 31.6% discount to trailing. This gap suggests that analysts anticipate a substantial increase in EPS, likely driven by cost synergies and operational improvements. The PEG ratio of 0.15x further underscores the market's expectation of high growth relative to valuation, though this low PEG may also reflect a low growth rate assumption.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. Cigna carries a debt-to-equity ratio of 0.75x, with interest expenses of $357 million in Q1 2026, which could strain earnings if rates rise. The company's gross margin is only 9.45%, reflecting the low-margin PBM business, and operating margin is a thin 3.32%, leaving little room for cost shocks. Revenue concentration is high, with Evernorth (PBM) contributing $58.44 billion of the $68.49 billion total, making the company vulnerable to PBM pricing pressures and regulatory changes. Additionally, the current ratio of 0.85x indicates potential liquidity concerns, though strong free cash flow of $7.66 billion TTM mitigates this risk.
FAQ
The key risks include: 1) Margin pressure in the PBM segment, as gross margin is only 9.45% and operating margin is 3.32%, leaving little room for cost increases. 2) Strategic execution risks from the exit of the individual exchange market and the eviCore review, which could disrupt operations. 3) High debt levels, with a debt-to-equity ratio of 0.75x, which could strain earnings if interest rates rise. 4) Competitive threats from UnitedHealth and CVS Health, which could lead to contract losses. The most severe risk is a margin compression that could reduce EPS and lead to a de-rating.
The 12-month forecast is based on three scenarios: a bull case (30% probability) with a target of $341-$400, driven by successful strategic execution and margin expansion; a base case (50% probability) with a target of $300-$341, assuming steady growth and stable margins; and a bear case (20% probability) with a target of $240-$290, if margins compress or contracts are lost. The most likely scenario is the base case, with the stock reaching the analyst average target of $341.42, assuming the company meets its raised guidance.
Cigna appears undervalued based on its forward PE of 8.44x, which is a 31.6% discount to its trailing PE of 12.34x, indicating the market expects significant earnings growth. The PEG ratio of 0.15x further suggests undervaluation relative to growth. Compared to peers, the stock trades at a discount, and the analyst average target of $341.42 implies a 20.8% upside. The market is pricing in modest growth, but if the company delivers on its guidance, the stock could re-rate higher.
Cigna is a good buy for value investors seeking a low valuation and solid cash flow. The stock trades at a forward PE of 8.44x, which is attractive given the expected EPS growth, and the analyst consensus is 'Buy' with a 20.8% upside to the average target. However, the stock has underperformed the market, and there are risks from margin pressure and strategic execution. If you are comfortable with these risks and have a medium-term horizon, it could be a good addition to a diversified portfolio.
Cigna is more suitable for long-term investment due to its low beta of 0.32, which provides stability, and its dividend yield of 2.2%, which offers income. The stock's growth is moderate at 4-5% revenue growth, and the strategic pivot may take time to deliver results. Short-term trading could be challenging given the stock's range-bound behavior and negative relative strength. A minimum holding period of 3-5 years is recommended to allow the strategic initiatives to play out and for the market to recognize the value.